PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.66%
R&D growth while AGEN reduces spending. John Neff would investigate strategic advantage.
40.35%
G&A growth while AGEN reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
24.17%
Other expenses growth less than half of AGEN's 120.53%. David Dodd would verify if advantage is sustainable.
22.03%
Operating expenses growth while AGEN reduces costs. John Neff would investigate differences.
22.03%
Total costs growth while AGEN reduces costs. John Neff would investigate differences.
-100.00%
Both companies reducing interest expense. Martin Whitman would check industry trends.
24.17%
D&A growth above 1.5x AGEN's 7.89%. Michael Burry would check for excessive investment.
-22.02%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-22.03%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-9.98%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-22.30%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
9.98%
Tax expense growth less than half of AGEN's 177.73%. David Dodd would verify if advantage is sustainable.
-22.30%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-22.29%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-22.29%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.